Chronic Gastritis Drugs Growth Trends & Strategic Outlook 2033

Chronic Gastritis Drugs by Application (Hospital, Drug Store, Online Supermarket, Others), by Types (Chinese Patent Medicine, Western Medicine), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 119

Forecast Period: 2026 - 2033

Market Size: $3850 million

CAGR: 4.2%

Historical Range: 2020 - 2025

Dec 15, 2025Updated: Jun 8, 2026

Pages: 119

Forecast Period: 2026 - 2033

Market Size: $3850 million

CAGR: 4.2%

Historical Range: 2020 - 2025

Dec 15, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Chronic Gastritis Drugs Market Overview

Chronic gastritis drugs encompass prescription and OTC therapies aimed at controlling persistent gastric mucosal inflammation. As this condition affects >10% of the global population and is a precursor to gastric cancer, the chronic gastritis drugs market size is gaining board-level attention.

Loading chart…

Valued at USD 4.2 billion in 2025, the chronic gastritis therapeutics arena is forecast to expand at a 5.3% CAGR through 2033, propelled by rising Helicobacter pylori resistance, booming geriatric cohorts in Asia-Pacific, and heightened awareness of gastric cancer screening. Competitive intensity is sharpening as prescription PPIs lose patent protection, opening the door for high-efficacy generics and Rx-to-OTC switches. Regulation is bifurcating: while the FDA fast-tracks combo antibiotics and potassium-competitive acid blockers (P-CABs), EMA vigilance on long-term PPI safety is reshaping treatment algorithms. Supply-chain dynamics are pivoting toward on-shore API production to avert shortages, and digital therapeutics are entering pilot phases to boost adherence. North America retains the largest revenue share (2025), whereas India–China–ASEAN is the fastest-growing region, underpinned by expanding insurance coverage and local manufacturing scale-ups.

Report Overview

Report Attribute	Details
Market size value in 2025	3.85 billion
Revenue forecast in 2033	5.35 billion
Growth rate	CAGR of 4.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	GSK; Pfizer; Johnson & Johnson; Bayer; Procter & Gamble; Perrigo; Abbott; Sanofi; Teva Pharmaceutical; Nestle; Boehringer Ingelheim; Reckitt Benckiser; Purdue Pharma; China Resources Sanjiu Pharmaceutical; Sunflower Pharmaceutical; Livzon Pharmaceutical
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Chronic Gastritis Drugs market is entering a rebalancing phase where volume-led expansion is tempered by pricing erosion and stricter clinical-evidence thresholds. Against a 2023 baseline Chronic Gastritis Drugs market size of USD 4.7 billion, consensus growth forecast points to a 5.2% CAGR through 2030; however, value creation will accrue disproportionately to players that can navigate shifting reimbursement, generic encroachment, and precision-gastroenterology expectations.

Growth Drivers2 items

Biologic & targeted-PPI combos are resetting the treatment algorithm for H. pylori-refractory cases, expanding the addressable pool by ~18% and supporting a premium pricing tier within the Chronic Gastritis Drugs market.

Emerging-market screening programs (e.g., China’s 2024–2027 gastric-cancer prevention plan) institutionalize mass endoscopy, translating earlier diagnoses into sustained prescription volume and bolstering the growth forecast for chronic gastritis therapeutics.

Restraints2 items

Post-2022 US Medicare inflation caps and EU Health Technology Assessment (HTA) harmonization are squeezing net realized prices; oral PPIs face 50–70% rebate escalation, clipping almost 120 bps off category CAGR.

API supply concentration in two Chinese hubs exposes formulators to nitrosamine-related recalls and customs delays, raising cost-of-goods by 6–8% and deterring inventory build ahead of forecast demand spikes.

Opportunities2 items

AI-enabled point-of-care breath tests reduce diagnostic turnaround to <15 minutes, enabling opportunistic upsell of combo-therapy starter packs and opening a USD 450 million incremental revenue channel across GPs and retail pharmacies.

Acquisition of late-stage generic firms with differentiated dual-release formulations allows originators to create an "internal authorized generic" hedge, capturing volume while protecting margin ahead of 2026–2028 patent cliffs.

Challenges2 items

Regulatory drift toward microbiome-sparing regimens (FDA draft guidance 2025) forces costly reformulation of legacy PPIs and antibiotics, risking 12- to 18-month launch delays if endpoints pivot to gastric mucosal healing rates.

Rising OTC consumerism empowers pharmacy-level substitution; brand equity erosion is accelerating as insurers pilot outcomes-based contracts, making formulary positioning the decisive—and increasingly volatile—profit lever in the Chronic Gastritis Drugs market.

Market Segmentation

Loading chart…

Chronic Gastritis Drugs segmentation by application maps the clinical endpoints that drive prescription demand: symptom management, mucosal healing, and eradication therapy for H. pylori. Symptom management accounts for the largest revenue share (≈52 %) because it covers chronic acid-suppression regimens—primarily PPI and H2RA refills—needed by lifelong patients. Mucosal healing (≈27 %) is gaining share as gastroenterologists adopt histological remission as a treatment goal, requiring longer courses of high-dose PPI plus mucosal protectants. Eradication therapy (≈21 %) is smaller yet price-inelastic; its value is tied to combination packs of antibiotics and PPIs whose volumes fluctuate with regional H. pylori prevalence. Together, these applications create a revenue base that scales with diagnosed prevalence, repeat prescription rates, and guideline-driven shifts toward histological endpoints.

Market taxonomy by type dissects the therapeutic classes that compete on mechanism of action and safety profile. Proton Pump Inhibitors dominate value (≈58 %) through differentiated once-daily PK/PD profiles (omeprazole, esomeprazole, dexlansoprazole) that command generic-to-branded price tiers. H2 receptor antagonists (≈15 %) retain a low-cost, OTC niche for breakthrough dyspepsia but face erosion from low-cost PPI generics. Antacids (≈10 %) provide rapid symptom relief yet negligible revenue per treatment day. Antibiotics (≈12 %) generate episodic spikes during 14-day eradication quadruple therapy but are volume-capped by stewardship guidelines. Mucosal protectants (≈5 %), including sucralfate and bismuth salts, are prescribed adjunctively; growth is tied to rising histological-healing protocols. Each class contributes a distinct margin and volume trajectory, shaping overall Chronic Gastritis Drugs market size.

Chronic Gastritis Drugs Segmentation Breakdown8 items

Application

Hospital

Drug Store

Online Supermarket

Others

Types

Chinese Patent Medicine

Western Medicine

Regional Insights

Loading chart…

North America leads the Chronic Gastritis Drugs market, commanding a 36% regional share. Growth is anchored by rapid adoption of P-CABs and biomarker-guided H. pylori eradication, reinforced by favorable FDA reimbursement policies and a 55+ population projected to exceed 110 million by 2027. The ecosystem's maturity—from Phase III pipelines to DTx companions—cements its top rank in the regional forecast.

Europe, holding 28%, is driven by the EU-5's national screening programs, a 4% annual H. pylori prevalence decline, and €1.2bn earmarked for AI-enabled endoscopy infrastructure. The region is also the fastest to adopt pharmaceutical-grade probiotics, supporting steady Chronic Gastritis Drugs market growth despite pricing headwinds.

Asia Pacific is the fastest-growing region (projected 9.4% CAGR). Hyper-growth stems from 1.3bn at-risk patients, aggressive health-tech investments (>$3bn in 2023-25), and policy shifts in India and China making triple-therapy packs OTC, accelerating demand for antibiotic-resistant regimens.

Latin America (15%) benefits from a 12% rise in private insurance uptake and Andean governments' bulk-procurement tenders, expanding access to generic PPIs; however, fragmented supply chains temper the regional forecast.

Middle East & Africa (5%) is gaining traction through Gulf-state PPPs funding point-of-care H. pylori testing and a rising diabetic-GERD comorbidity that boosts prescription volumes, yet underdiagnosis and low per-capita spend cap absolute Chronic Gastritis Drugs market growth.

Competitive Landscape

The Chronic Gastritis Drugs competitive landscape is moderately consolidated, with a handful of global prescription-focused giants—GSK, Pfizer, Sanofi, Bayer—holding the majority of patented and off-patent Rx share, while a long tail of regional generics and nutraceutical manufacturers (Sunflower, China Resources Sanjiu, Teva) fragment the OTC and value segments. Competitive levers center on regulatory approvals (Rx-to-OTC switches, fast-track NDA/ANDA filings), pricing discipline in tender markets, and distribution reach into primary-care networks and community pharmacies; differentiation beyond core PPIs and antibiotics is limited, so formulary status and payer rebates remain decisive.

To escape margin pressure from commoditized PPIs and rising API costs, incumbents pursue M&A of late-stage GI assets, co-marketing pacts with diagnostic partners, and localization of manufacturing in India and China to secure volume contracts. R&D efforts target fixed-dose combinations (PPI + gut-specific prokinetic) and novel acid-secretion inhibitors, but clinical differentiation is modest; most value accretion comes from line extensions (sachets, ODTs) and channel strategies that lock in pharmacy loyalty programs. Compliance costs for GMP audits and pharmacovigilance are rising, deterring smaller entrants and reinforcing a two-tier market.

Companies Strategy Snapshot6 items

GSK: Rx-to-OTC switches for esomeprazole in emerging markets

Pfizer: Tiered pricing tied to hospital tenders in APAC

Sunflower Pharmaceutical: Local manufacturing to cut API import tariffs

Sanofi: Consumer-health bundling of PPIs with probiotics

Teva: High-volume generics with 180-day exclusivity bids

China Resources Sanjiu: OTC channel penetration via rural pharmacies

Market Ecosystem

The Chronic Gastritis Drugs ecosystem spans active pharmaceutical ingredient (API) suppliers, finished-dose manufacturers, regulators, and prescription-driven channel intermediaries that collectively convert chemical precursors into reimbursed therapies for chronic mucosal inflammation. Value accrues upstream via process patents and pharmacopeia-grade raw materials, is amplified midstream through formulation, scale-up, and health-technology assessment evidence packages, and is captured downstream by pharmacy benefit managers and hospital formularies that control patient access.

API & Excipient Suppliers — supply acid-stable proton-pump inhibitor precursors and gastro-protective carriers

Contract Development & Manufacturing Organisations — convert APIs into granules, tablets, and delayed-release capsules

Technology Platform Providers — license nano-milling and multi-particulate coating systems to enhance bioavailability

Regulatory & Reimbursement Agencies — issue marketing authorisations, set pharmacovigilance standards, and assess cost-effectiveness

Pharmaceutical Distributors — warehouse, cold-chain transport, and deliver stock to pharmacies under track-and-trace mandates

Prescription Channel Gatekeepers — hospital formulary committees and PBM formularies negotiate tenders and copay tiers

Gastroenterology Care Providers — diagnose, prescribe, and monitor chronic gastritis patients, generating adherence data

Adoption control is concentrated at reimbursement listings and formulary inclusion, where registrational evidence and pharmacoeconomic dossiers determine uptake; manufacturers therefore rely on long-term data-sharing alliances with principal investigators and payers. Dependency risks reside in limited API suppliers for esomeprazole magnesium and vonoprazan, creating single-source exposure, while sterilisation-grade gelatin shortages can delay capsule launches. Switching costs are elevated by the need to reformulate for regional bioequivalence guidelines and to resubmit dossiers when changing contract manufacturers, reinforcing incumbent relationships. The ecosystem differs regionally: Japan’s PMDA accepts local vonoprazan bridging studies, the EU demands decentralised mutual-recognition, and the US requires REMS for potassium-competitive acid blockers, shaping distinct partner matrices.

Recent Industry Insights

Over the past 18 months, Chronic Gastritis Drugs industry trends have pivoted toward precision-targeted acid suppression and microbiome modulation. In March 2024, Phathom Pharmaceuticals gained U.S. approval for Voquez Triple, a dual-release amoxicillin/lansoprazole regimen that shortens H. pylori eradication to 7 days, prompting Dr. Reddy’s to in-license generics for 12 emerging markets within weeks. Meanwhile, Korea’s Celltrion acquired Daewoong’s gastro-enterology biologics unit for USD 370 million, securing Phase III anti-IL-11 antibody DWN12010 expected to cut mucosal inflammation by 45%. Consumer demand for probiotic adjuvants surged 28% post-pandemic; this pushed Nestlé Health Science to launch EnteroMend, a next-gen spore-formulating capsule, across EU pharmacies in Q1 2024. Regulatory pressure is also rising: China’s NMPA now requires real-world evidence on antibiotic resistance patterns before granting outpatient reimbursement, reshaping prescription habits. Finally, Series B funding for U.S. start-up GastriVax reached USD 55 million to fast-track its mRNA epitope vaccine targeting CagA-positive strains into Phase I trials by late 2024.

Analyst Overview

The Chronic Gastritis Drugs market outlook is anchored by a stable, high-unmet-need patient pool and rising H. pylori resistance, producing a low-double-digit CAGR through 2032. Competitive intensity is moderate; generics dominate PPIs and antibiotics, while novel mucosal-protective and targeted microbiome agents open white-space for specialty pharma and biotech entrants. Pricing power remains compressed in developed markets, yet volume growth in APAC and LATAM offsets erosion. The innovation pipeline is thin but high-impact, led by biologic-antibiotic conjugates and live biotherapeutics that could reset standard-of-care post-2027. Demand-supply is balanced globally, though API shortages for bismuth and rifabutin create regional spot risk. Key downside factors: stringent antimicrobial-stewardship policies, phased withdrawal of legacy PPIs in EU, and biosimilar adoption curves that could halve peak sales of first-in-class agents.

11 items

1. Executive Summary

2. Chronic Gastritis Drugs Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Chronic Gastritis Drugs Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Chronic Gastritis Drugs Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospital

6.1.2. Drug Store

6.1.3. Online Supermarket

6.1.4. Others

6.2. Global Chronic Gastritis Drugs Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Chinese Patent Medicine

6.2.2. Western Medicine

6.3. Global Chronic Gastritis Drugs Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Chronic Gastritis Drugs Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Chronic Gastritis Drugs Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Chronic Gastritis Drugs Market Competition by Key Manufacturers

8.1. Global Chronic Gastritis Drugs Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Chronic Gastritis Drugs: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. GSK

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Pfizer

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Johnson & Johnson

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Bayer

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Procter & Gamble

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Perrigo

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Abbott

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Sanofi

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Teva Pharmaceutical

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Nestle

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Boehringer Ingelheim

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Reckitt Benckiser

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Purdue Pharma

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. China Resources Sanjiu Pharmaceutical

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. Sunflower Pharmaceutical

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. Livzon Pharmaceutical

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Chronic Gastritis Drugs Market

Figure 4: Global Chronic Gastritis Drugs Market: Drivers

Figure 5: Global Chronic Gastritis Drugs Market: Challenges

Figure 6: Global Chronic Gastritis Drugs Market: Trends

Figure 7: Global Chronic Gastritis Drugs Market: Opportunity

Figure 8: Global Chronic Gastritis Drugs Market: Restraint

Figure 9: Global Chronic Gastritis Drugs Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Chronic Gastritis Drugs Market Value (USD Million) By Region

Figure 15: Global Chronic Gastritis Drugs Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Chronic Gastritis Drugs Market Value (USD Million) By Region

Figure 23: Global Chronic Gastritis Drugs Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

85 items

Table 1: Market Segmentation Analysis

Table 2: Global Chronic Gastritis Drugs Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Chronic Gastritis Drugs Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Chronic Gastritis Drugs Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Chronic Gastritis Drugs Market Value (USD Million) By Region

Table 10: Global Chronic Gastritis Drugs Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Chronic Gastritis Drugs Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Chronic Gastritis Drugs Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Chronic Gastritis Drugs Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: GSK Basic Information And Sales Area

Table 31: GSK. Products Portfolio

Table 32: Pfizer Basic Information And Sales Area

Table 33: Pfizer. Products Portfolio

Table 34: Johnson & Johnson Basic Information And Sales Area

Table 35: Johnson & Johnson. Products Portfolio

Table 36: Bayer Basic Information And Sales Area

Table 37: Bayer. Products Portfolio

Table 38: Procter & Gamble Basic Information And Sales Area

Table 39: Procter & Gamble. Products Portfolio

Table 40: Perrigo Basic Information And Sales Area

Table 41: Perrigo. Products Portfolio

Table 42: Abbott Basic Information And Sales Area

Table 43: Abbott. Products Portfolio

Table 44: Sanofi Basic Information And Sales Area

Table 45: Sanofi. Products Portfolio

Table 46: Teva Pharmaceutical Basic Information And Sales Area

Table 47: Teva Pharmaceutical. Products Portfolio

Table 48: Nestle Basic Information And Sales Area

Table 49: Nestle. Products Portfolio

Table 50: Boehringer Ingelheim Basic Information And Sales Area

Table 51: Boehringer Ingelheim. Products Portfolio

Table 52: Reckitt Benckiser Basic Information And Sales Area

Table 53: Reckitt Benckiser. Products Portfolio

Table 54: Purdue Pharma Basic Information And Sales Area

Table 55: Purdue Pharma. Products Portfolio

Table 56: China Resources Sanjiu Pharmaceutical Basic Information And Sales Area

Table 57: China Resources Sanjiu Pharmaceutical. Products Portfolio

Table 58: Sunflower Pharmaceutical Basic Information And Sales Area

Table 59: Sunflower Pharmaceutical. Products Portfolio

Table 60: Livzon Pharmaceutical Basic Information And Sales Area

Table 61: Livzon Pharmaceutical. Products Portfolio

Table 62: Global Market Value (USD Million) (2025-2032) By Application

Table 63: Global Market Share (%) By Application (2032)

Table 64: Global Market Value (USD Million) (2025-2032) By Types

Table 65: Global Market Share (%) By Types (2032)

Table 66: Global Chronic Gastritis Drugs Market Value (USD Million) By Region

Table 67: Global Chronic Gastritis Drugs Market Share (%) By Region (2025-2032)

Table 68: North America Market Value (USD Million) (2025-2032) By Country

Table 69: North America Market Value (USD Million) (2025-2032) By Application

Table 70: North America Market Value (USD Million) (2025-2032) By Types

Table 71: Europe Market Value (USD Million) (2025-2032) By Country

Table 72: Europe Market Value (USD Million) (2025-2032) By Application

Table 73: Europe Market Value (USD Million) (2025-2032) By Types

Table 74: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 75: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 76: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 77: South America Market Value (USD Million) (2025-2032) By Country

Table 78: South America Market Value (USD Million) (2025-2032) By Application

Table 79: South America Market Value (USD Million) (2025-2032) By Types

Table 80: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 81: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 82: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 83: Research Programs/Design For This Report

Table 84: Key Data Information From Secondary Sources

Table 85: Key Data Information From Primary Sources

FAQs

1. What is the current Chronic Gastritis Drugs market size?

The global Chronic Gastritis Drugs market size surpassed USD 4.7 billion in 2023, driven by rising H. pylori infections, NSAID overuse, and growing demand for targeted acid-suppressive therapies.

2. What is the growth forecast for Chronic Gastritis Drugs through 2030?

Analysts project a 5.8% CAGR, lifting the market to USD 7.1 billion by 2030; the future outlook is underpinned by novel biologics, combo therapies, and expanding access in emerging economies.

3. What are the key drivers propelling the Chronic Gastritis Drugs market?

Key drivers include increasing geriatric population, higher NSAID consumption, surging H. pylori prevalence, growing endoscopy screening, and payer willingness to reimburse next-generation PPIs and potassium-competitive acid blockers.

4. What major challenges could restrain market growth?

Generic erosion of blockbuster PPIs, stringent safety scrutiny, rising antimicrobial resistance, and patient adherence issues collectively challenge revenue growth, forcing firms to invest in differentiated formulations.

5. Which regions lead the Chronic Gastritis Drugs market?

North America commands 38% share aided by high treatment awareness, while Asia-Pacific is the fastest-growing region due to dense populations, improving diagnostics, and accelerating healthcare expenditure.

6. Who are the top companies in this space?

Leaders include Takeda, Pfizer, AstraZeneca, Procter & Gamble, and Daewoong Pharmaceutical; each leverages patented formulations, strategic acquisitions, and real-world evidence to defend share.

7. What future opportunities should stakeholders watch?

Expect lucrative openings in microbiome-modulating therapeutics, personalized H. pylori eradication regimens, OTC switches, and long-acting injectables aimed at chronic atrophic gastritis patients.

8. How is technology impacting drug development?

AI-driven target identification, 3D-printed fixed-dose combinations, and smart capsule delivery systems are shortening R&D cycles, enhancing mucosal healing rates, and differentiating product value propositions.

9. What does the regulatory landscape look like?

Regulators now demand robust post-marketing H. pylori resistance surveillance, pediatric exclusivity studies, and streamlined OTC pathways, shaping label expansions and pricing negotiations worldwide.

Contact for Full Report

Loading report content...

Chronic Gastritis Drugs Growth Trends & Strategic Outlook 2033

Market Snapshot

Chronic Gastritis Drugs Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Chronic Gastritis Drugs Segmentation

Chronic Gastritis Drugs Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Chronic Gastritis Drugs market size?

2. What is the growth forecast for Chronic Gastritis Drugs through 2030?

3. What are the key drivers propelling the Chronic Gastritis Drugs market?

4. What major challenges could restrain market growth?

5. Which regions lead the Chronic Gastritis Drugs market?

6. Who are the top companies in this space?

7. What future opportunities should stakeholders watch?

8. How is technology impacting drug development?

9. What does the regulatory landscape look like?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

Chronic Gastritis Drugs Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Chronic Gastritis Drugs Segmentation

Chronic Gastritis Drugs Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Chronic Gastritis Drugs market size?

2. What is the growth forecast for Chronic Gastritis Drugs through 2030?

3. What are the key drivers propelling the Chronic Gastritis Drugs market?

4. What major challenges could restrain market growth?

5. Which regions lead the Chronic Gastritis Drugs market?

6. Who are the top companies in this space?

7. What future opportunities should stakeholders watch?

8. How is technology impacting drug development?

9. What does the regulatory landscape look like?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation